InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.018 0 (0%)+
Announcement
Release
23 Jul 2026 9:46AM
Price at Release
$0.018
Full Release
download
Summary
Atomo Diagnostics Limited reported strong financial performance for Q4 FY2026, with revenue of $2.3 million for the quarter, totaling $5.3 million for the full year, marking a 40% increase from FY25. The company received sales orders exceeding $1.5 million and achieved cash receipts of $3.8 million, closing the quarter with $3.7 million in cash and remaining debt-free. The quarter saw growth in the distribution of the Atomo HIV Self-Test, with a 33% increase in Australian pharmacies carrying the product. Additionally, Atomo completed orders for new OEM customers, progressed the Atomo Liver function test, and improved operational capabilities with the setup of a new blister machine. The Appendix 4C cash flow report highlighted net cash usage in operations and investments, with a focus on expanding revenue channels, including launching new products like the syphilis and liver tests.
Key Points
  • Revenue for Q4 FY26 was $2.3 million, totaling $5.3 million for FY26, up 40% from FY25.
  • Sales orders over $1.5 million received during the quarter.
  • Cash receipts totaled $3.8 million with cash on hand at $3.7 million, and the company remains debt-free.
  • 33% increase in Australian pharmacies selling the Atomo HIV Self-Test.
  • Completion of orders for two new OEM customers, supporting long-term agreements.
  • Progress on Atomo Liver function test for patients on at-risk drugs.
  • Setup and operation of a second-generation blister machine in Sydney.
  • Appendix 4C report shows cash flow activities with a focus on revenue growth and product expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.